The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Open accessAbstract
Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a complex consisting of YAP, TAZ, TEADs, and AP-1 (dimer of cFos and transcription factor Jun [JUN] families) was found to synergistically regulate the transcription of target genes (35–37).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have demonstrated that activated Yap, through genetic amplification of YAP- or WNT5a-mediated dysregulation of the Hippo pathway, enables bypass of Kras suppression in Kras-driven murine pancreatic cancer and lung cancer models (37–39).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“YAP, a pivotal EMT regulator gene, can restore oncogenicity in murine tumors that have lost KRAS [54,131].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies using inducible suppression of KRAS via RNA interference or genetically engineered inducible KrasG12D alleles (i.e., “iKras” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRASG12D suppression (35–38).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using a genetically engineered mouse (GEM) model of PDAC driven by inducible KRASG12D, we recently demonstrated that activation of the YAP1 oncogene drives resistance to genetic inactivation of KRAS∗, a finding further confirmed in KRAS∗-driven colorectal cancer (CRC).”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The YAP1 oncogene has been well established as one of the major drivers of bypassing oncogene addiction and promoting acquired resistance to targeted therapies in several cancer types, including pancreatic cancer, lung cancer, colorectal cancer, melanoma, and glioblastoma.9,10,38,39,40”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“In the context of pancreatic cancer, KRAS dependency can be by-passed by the elevated expression of the transcription factor YAP1, which promotes EMT and confers cell-intrinsic resistance to KRAS loss (84, 85).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [84]
In the citing paper
“On the one hand, it is known that YAP activity is positively correlated with the resistance to therapies targeting KRAS signaling components including RAF and MEK,[ 28, 46 ] and YAP is required for KRAS‐dependent cell transformation: extracellular supplementation of YAP activators can rescue cancer cell killing after KRAS knockdown.[ 47 ]”
From Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Self-citationTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,423
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citation
Flagged first, then by citations
1 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 753
The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma
Cadamuro, M., Stecca, T., Brivio, S., Mariotti, V., Fiorotto, R., Spirlı̀, C., Strazzabosco, M., & Fabris, L. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.028 · Cited by 76
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
Self-citationYAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130811 · Cited by 75
The deadly cross-talk between Hippo pathway and epithelial–mesenchymal transition (EMT) in cancer
Ακρίδα, Ι., Bravou, V., & Papadaki, H. H. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07590-z · Cited by 73
Cancer stem cells: a potential target for cancer therapy
Qiu, H. Y., Fang, X., Luo, Q., & Ouyang, G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1920-4 · Cited by 72
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Espinosa-Sánchez, A., Suárez-Martínez, E., Sánchez-Díaz, L., & Carnero, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01533 · Cited by 77
Bugg, D., Bretherton, R. C., Kim, P., Olszewski, E., Nagle, A., Schumacher, A. E., Chu, N., Gunaje, J. J., DeForest, C. A., Stevens, K. R., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316162 · Cited by 70
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
Barry, E., Simov, V., Valtingojer, I., & Venier, O. (2021) · Cells · doi:10.3390/cells10102715 · Cited by 73
Oncogenic KRAS signaling and YAP1/β-catenin: Similar cell cycle control in tumor initiation
Nussinov, R., Tsai, C., Jang, H., Korcsmáros, T., & Csermely, P. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.04.001 · Cited by 70
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 74
Yang, W., Yang, S., Zhang, F., Cheng, F., Wang, X., & Rao, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.11 · Cited by 70
Self-citationAutocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers
Rajbhandari, N., Lin, W.-C., Wehde, B. L., Triplett, A. A., & Wagner, K.-U. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.013 · Cited by 68
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 68
Jiang, Z., Zhou, C., Cheng, L., Yan, B., Chen, K., Chen, X., Zong, L., Lei, J., Duan, W., Xu, Q., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0740-4 · Cited by 69
Liu, Z., Wei, Y., Zhang, L., Yee, P. P., Johnson, M., Zhang, X., Gulley, M., Atkinson, J. M., Trebak, M., Wang, H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0425-7 · Cited by 68
Yan, H., Li, H., Li, P., Li, X., Lin, J., Zhu, L., Silva, M. A., Wang, X., Wang, P., & Zhang, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0910-4 · Cited by 67
Self-citationRetractedYAP-Induced Endothelial-Mesenchymal Transition in Oral Submucous Fibrosis
Li, J., Yao, M., Zhu, X., Li, Q., He, J. B., Chen, L., Wang, W., Zhu, C., Shen, T., Cao, R., et al. (2019) · Journal of Dental Research · doi:10.1177/0022034519851804 · Cited by 67
Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation
Gao, H., Chakraborty, G., Lee-Lim, A. P., Mavrakis, K. J., Wendel, H., & Giancotti, F. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403234111 · Cited by 67
Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation
Lim, N., & Townsend, P. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32900 · Cited by 67
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 76
Muranen, T. E., Selfors, L. M., Hwang, J., Gallegos, L. L., Coloff, J. L., Thoreen, C. C., Kang, S. A. W., Sabatini, D. M., Mills, G. B., & Brugge, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0155 · Cited by 66
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 86
Targeting the Hippo pathway in cancer
Harvey, K. F., & Tang, T. T.-L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01234-0 · Cited by 68
Li, S., Yu, Z., Chen, S., Li, F., Lei, C., Chen, X.-X., Bao, J., Luo, Y., Lin, G., Pang, S., et al. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.06.003 · Cited by 64
Mayrhofer, M., Gourain, V., Reischl, M., Affaticati, P., Jenett, A., Joly, J., Benelli, M., Demichelis, F., Poliani, P. L., Sieger, D., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.026500 · Cited by 68
Shin, S., Kim, J., Park, S.-W., Jun, S.-Y., Kweon, H.-J., Choi, D.-K., Lee, D., Cho, Y. B., & Kim, Y. (2020) · Science Advances · doi:10.1126/sciadv.aay2174 · Cited by 63
Self-citationRole of Yes-associated protein in cancer: An update
Abylkassov, R., & Xie, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4955 · Cited by 64
Guo, P.-D., Lu, X.-X., Gan, W.-J., Li, X., He, X., Zhang, S., Ji, Q., Zhou, F., Cao, Y. Z., Wang, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2882 · Cited by 62
Dual roles of yes-associated protein (YAP) in colorectal cancer
Ou, C., Sun, Z., Li, S., Li, G., Li, X., & Ma, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20155 · Cited by 62
YAP1 is essential for osteoclastogenesis through a TEADs-dependent mechanism
Zhao, L., Guan, H., Song, C., Wang, Y., Liu, C. Y., Cai, C., Liu, H., Liu, H., Zhao, L., & Xiao, J. (2018) · Bone · doi:10.1016/j.bone.2018.01.035 · Cited by 64
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Santoro, R., Zanotto, M., Simionato, F., Zecchetto, C., Merz, V., Cavallini, C., Piro, G., Sabbadini, F., Boschi, F., Scarpa, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0270 · Cited by 61
YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
Coggins, G. E., Farrel, A., Rathi, K. S., Hayes, C. M., Scolaro, L., Rokita, J. L., & Maris, J. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1415 · Cited by 66
Emerging Principles in the Transcriptional Control by YAP and TAZ
Lopez-Hernandez, A., Sberna, S., & Campaner, S. (2021) · Cancers · doi:10.3390/cancers13164242 · Cited by 60
Mechanisms of YAP/TAZ transcriptional control
Battilana, G., Zanconato, F., & Piccolo, S. (2021) · Cell Stress · doi:10.15698/cst2021.11.258 · Cited by 60
FGF8 promotes colorectal cancer growth and metastasis by activating YAP1
Liu, R. R., Huang, S., Lei, Y., Zhang, T., Wang, K., Liu, B., Nice, E. C., Xiang, R., Xie, K., Li, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2822 · Cited by 61
Multifunctional DDX3: dual roles in various cancer development and its related signaling pathways.
Zhao, L., Mao, Y., Zhou, J., Zhao, Y., Cao, Y., & Chen, X. '. (2016) · PubMed Central · Cited by 60
Guerrant, W., Kota, S., Troutman, S. A., Mandati, V., Fallahi, M., Stemmer-Rachamimov, A. O., & Kissil, J. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1144 · Cited by 60
Meng, J., Zhang, X., Liu, X., Fan, L., Li, C., Sun, Y., Liang, X., Wang, J., Mei, Q., Zhang, F., et al. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.07.008 · Cited by 60
The NDR/LATS protein kinases in immunology and cancer biology
Sharif, A. A. D., & Hergovich, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.010 · Cited by 60
YAP1-TEAD1 signaling controls angiogenesis and mitochondrial biogenesis through PGC1α
Mammoto, A., Muyleart, M., Kadlec, A. O., Gutterman, D. D., & Mammoto, T. (2018) · Microvascular Research · doi:10.1016/j.mvr.2018.04.003 · Cited by 60
Sethunath, V., Hu, H., Angelis, C. D., Veeraraghavan, J., Qin, L., Wang, N., Simon, L. M., Wang, T., Fu, X., Nardone, A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0756 · Cited by 60
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“Cell lines resistant to PROTACs were rendered sensitive by genetic and pharmacological MDR1 inhibition, suggesting a combinatorial strategy involving KRAS PROTACs and MDR1 inhibitors [134].”
BackgroundEffects of RNA methylation on Tumor angiogenesis and cancer progression
Han, M., Sun, H., Zhou, Q., Liu, J., Hu, J., Yuan, W., & Sun, Z. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01879-8 · Cited by 59
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 58
Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58
MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling
Chang, R., Xu, J., Fang, F., Yang, H., & Yang, L. (2016) · Tumor Biology · doi:10.1007/s13277-016-4919-z · Cited by 57
Yap/Taz promote the scavenging of extracellular nutrients through macropinocytosisPreprint
King, B., Araki, J., Palm, W., & Thompson, C. B. (2020) · Genes & Development · doi:10.1101/gad.340661.120 · Cited by 56
Signaling pathways and mesenchymal transition in pediatric high-grade glioma
Meel, M. H., Schaper, S. A., Kaspers, G. J. L., & Hulleman, E. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2714-7 · Cited by 58
Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors
Chowanadisai, W., Messerli, S. M., Miller, D. H., Medina, J. E., Hamilton, J. W., Messerli, M. A., & Brodsky, A. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151089 · Cited by 56
YAP and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in Mice
Park, J., Eisenbarth, D., Choi, W., Kim, H., Choi, C., Lee, D., & Lim, D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0907 · Cited by 59
Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103592118 · Cited by 55
Fesler, A. T., Liu, H., & Ju, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23414 · Cited by 54
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells
Kim, J. W., Berrios, C. J., Kim, M., Schade, A. E., Adelmant, G., Yeerna, H., Damato, E., Iniguez, A. B., Swanson, S. K., Florens, L. A., et al. (2020) · eLife · doi:10.7554/elife.53003 · Cited by 54
Self-citationFunctional antagonism of chromatin modulators regulates epithelial-mesenchymal transition
Serresi, M., Kertalli, S., Li, L., Schmitt, M. J., Dramaretska, Y., Wierikx, J., Hulsman, D., & Gargiulo, G. (2021) · Science Advances · doi:10.1126/sciadv.abd7974 · Cited by 50
Nie, H., Huang, P.-Q., Jiang, S.-H., Yang, Q., Hu, L.-P., Yang, X., Li, J., Wang, Y., Li, Q., Zhang, Y., et al. (2021) · Theranostics · doi:10.7150/thno.51712 · Cited by 52
Jia, J., Li, C., Luo, S., Liu, F., Yang, J., Wang, X., Wang, N., Lai, B., Lei, T., Wang, Q., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.02.005 · Cited by 53
Self-citationJiménez, A. P., Traum, A., Boettger, T., Hackstein, H., Richter, A. M., & Dammann, R. (2017) · Oncotarget · doi:10.18632/oncotarget.18177 · Cited by 54
Vivekanandhan, S., & Mukhopadhyay, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.014 · Cited by 53
Sambandam, S. A. T., Kasetti, R. B., Xue, L., Dean, D. C., Lu, Q., & Li, Q. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.42 · Cited by 52
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States
Kim, J. W., Abudayyeh, O. O., Yeerna, H., Yeang, C., Stewart, M. L., Jenkins, R. W., Kitajima, S., Konieczkowski, D. J., Medetgul-Ernar, K., Cavazos, T. B., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.08.002 · Cited by 49
Self-citationYAP in pancreatic cancer: oncogenic role and therapeutic strategy
Mao, W., Mai, J., Peng, H., Wan, J., & Sun, T. (2020) · Theranostics · doi:10.7150/thno.53438 · Cited by 54
Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma
Slemmons, K. K., Crose, L. E. S., Rudzinski, E. R., Bentley, R. C., & Linardic, C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140781 · Cited by 51
Herranz, H., Eichenlaub, T., & Cohen, S. M. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2015.11.037 · Cited by 52
MOB (Mps one Binder) Proteins in the Hippo Pathway and Cancer
Gündoğdu, R., & Hergovich, A. (2019) · Cells · doi:10.3390/cells8060569 · Cited by 50
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Deng, D., Patel, R. H., Chiang, C.-Y., & Hou, P. (2022) · Cells · doi:10.3390/cells11192952 · Cited by 53
Wu, D., Lin, P.-L., Wang, L., Huang, C., & Lee, H. (2017) · Theranostics · doi:10.7150/thno.18175 · Cited by 51
Paxillin family of focal adhesion adaptor proteins and regulation of cancer cell invasion
Alpha, K. M., Xu, W., & Turner, C. E. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.05.003 · Cited by 50
Fisher, J. G., Tait, D. L., Garrett-Mayer, E. S., Halabi, S., Mangat, P. K., Schink, J. C., Álvarez, R. H., Veljovich, D. S., Cannon, T. L., Crilley, P. A., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00753-7 · Cited by 50
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
Tian, Y., Tang, B., Wang, C., Sun, D., Zhang, R., Luo, N., Zhao, H., Liang, R., Gao, Z., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.10079 · Cited by 49
The roles of ubiquitin modifying enzymes in neoplastic disease
Kumari, N., Jaynes, P. W., Saei, A., Iyengar, P. V., Richard, J. L. C., & Eichhorn, P. J. A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.002 · Cited by 51
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma
Hayes, T. K., Luo, F., Cohen, O., Goodale, A. B., Lee, Y., Pantel, S., Bagul, M., Piccioni, F., Root, D. E., Garraway, L. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2711 · Cited by 48
Self-citationCheng, D., Jin, L., Chen, Y., Xi, X., & Guo, Y. (2020) · PubMed Central · Cited by 49
Chao, Y., Lee, K., Wu, S., Kuo, D., Shueng, P., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115649 · Cited by 47
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Kumar, R., & Hong, W. (2024) · Cells · doi:10.3390/cells13070564 · Cited by 47
MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer
Huang, C., Ma, R., Yue, J., Li, N., Li, Z., & Qi, D. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430358 · Cited by 47
Yeh, Y.-W., Cheng, C.-C., Yang, S.-T., Tseng, C.-F., Chang, T.-Y., Tsai, S.-Y., Fu, E., Chiang, C., Liao, L.-C., Tsai, P.-W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13629 · Cited by 47
YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
Sun, T., Mao, W., Peng, H., Wang, Q., & Jiao, L. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00595-z · Cited by 47
CRIM1, a newfound cancer-related player, regulates the adhesion and migration of lung cancer cells
Zeng, H., Zhang, Y., Yi, Q., Wu, Y., Wan, R., & Tang, L. (2015) · Growth Factors · doi:10.3109/08977194.2015.1119132 · Cited by 46
YAP and the drug resistance highway
Keren‐Paz, A., Emmanuel, R., & Samuels, Y. (2015) · Nature Genetics · doi:10.1038/ng.3228 · Cited by 45
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, H., Moore, J., Malonia, S. K., Li, Y., Ozata, D. M., Hough, S., Song, C.-Q., Smith, J. L., Fischer, A., Weng, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620861114 · Cited by 46
Self-citationAdaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen, P., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A. J., Rosario, A. M. D., Mertins, P., Qiao, J., Schäfer, C., Gertler, F. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 47
Self-citationSantoro, R., Zanotto, M., Carbone, C., Piro, G., Tortora, G., & Melisi, D. (2018) · Anticancer Research · doi:10.21873/anticanres.12431 · Cited by 46
Hippo signaling dysfunction induces cancer cell addiction to YAP
Han, H., Yang, B., Nakaoka, H. J., Yang, J., Zhao, Y., Nguyen, K. L., Bishara, A. T., Mandalia, T. K., & Wang, W. (2018) · Oncogene · doi:10.1038/s41388-018-0419-5 · Cited by 46
Circular RNA Vav3 sponges gga-miR-375 to promote epithelial-mesenchymal transition
Zhang, X., Yan, Y., Lin, W., Li, A., Zhang, H., Lei, X., Dai, Z., Li, X., Li, H., Chen, W., et al. (2019) · RNA Biology · doi:10.1080/15476286.2018.1564462 · Cited by 45
Hein, A. L., Brandquist, N. D., Ouellette, C. Y., Seshacharyulu, P., Enke, C. A., Ouellette, M. M., Batra, S. K., & Yan, Y. (2019) · Oncogenesis · doi:10.1038/s41389-019-0172-9 · Cited by 46
Zhu, M. L., Peng, R., Liang, X., Lan, Z., Tang, M., Hou, P., Song, J. H., Mak, C. S. L., Park, J., Zheng, S.-E., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02000-3 · Cited by 46
Hu, L., Sun, Y., Liu, S., Erb, H., Singh, A., Mao, J., Luo, X., & Wu, X. (2022) · eLife · doi:10.7554/elife.80210 · Cited by 49
Ma, J., Zhao, J., Lü, J., Wang, P., Feng, H., Zong, Y., Ou, B., Zheng, M., & Lu, A. (2016) · Tumor Biology · doi:10.1007/s13277-015-4555-z · Cited by 45
Endothelin‐1 Drives Epithelial‐Mesenchymal Transition in Hypertensive Nephroangiosclerosis
Seccia, T. M., Caroccia, B., Gioco, F., Piazza, M., Buccella, V., Guidolin, D., Guerzoni, E., Montini, B., Petrelli, L., Pagnin, E., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003888 · Cited by 46
Increased Hemodynamic Load in Early Embryonic Stages Alters Endocardial to Mesenchymal Transition
Midgett, M., López, C. S., David, L. L., Maloyan, A., & Rugonyi, S. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00056 · Cited by 48
Chen, N., Golczer, G., Ghose, S., Lin, B., Langenbucher, A., Webb, J., Bhanot, H., Abt, N. B., Lin, D. T., Varvares, M. A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110970 · Cited by 45
HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway
Xu, J., Xuejiao, F., Long, L., Wang, S., Qian, S., & Lyu, J. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1832429 · Cited by 44
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Amot and Yap1 regulate neuronal dendritic tree complexity and locomotor coordination in mice
Rojek, K. O., Krzemień, J., Doleżyczek, H., Boguszewski, P. M., Kaczmarek, L., Konopka, W., Rylski, M., Jaworski, J., Holmgren, L., & Prószyński, T. J. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000253 · Cited by 45
Mammoto, T., Torisawa, Y.-S., Muyleart, M., Hendee, K., Anugwom, C., Gutterman, D., & Mammoto, A. (2019) · Aging · doi:10.18632/aging.102236 · Cited by 43
Corvaisier, M., Bauzone, M., Corfiotti, F., Renaud, F., Amrani, M. E., Monté, D., Truant, S., Leteurtre, E., Formstecher, P., SEUNINGEN, I. V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11057 · Cited by 45
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Lee, J.-M., Hays, J. L., Chiou, V. L., Annunziata, C. M., Swisher, E. M., Harrell, M. I., Yu, M., Gordon, N., Sissung, T. M., Ji, J. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16577 · Cited by 43
Wang, J., Li, H., Xia, C., Yang, X., Dai, B., Tao, K., & Dou, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s190061 · Cited by 43
Song, S., Wang, Z., Li, Y., Ma, L., Jin, J., Scott, A. W., Xu, Y., Estrella, J. S., Song, Y., Liu, B., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0895 · Cited by 43
Metadata
- Authors
- Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., Zwang, Y., Roberts, T. M., Root, D. E., Jacks, T., & Hahn, W. C.
- Affiliations
- Broad Institute (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Jacks, Tyler
- Hahn, William C.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 158
- Issue
- 1
- Pages
- 171-184
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4110062
- OpenAlex
- W2064644124
- Cited by
- 744
- References
- 69
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 50 · 2023: 56 · 2022: 59 · 2021: 58 · 2020: 82 · 2019: 68 · 2018: 58 · 2017: 73 · 2016: 75 · 2015: 61 · 2014: 22
- FWCI
- 38.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (P30-CA14051, W81XWH)
- Howard Hughes Medical Institute
- American Association for Cancer Research
- Hope Funds for Cancer Research (HFCR-11-03-03)
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051)
- National Institutes of Health (W81XWH)
- National Cancer Institute (P50CA127003, K99CA169512, R01CA140545, CA14051, R00CA169512, P01CA050661, U01CA176058, P01CA154303, P30CA014051, P30-CA-14051)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- KRAS, YAP, oncogenic Ras, epithelial-mesenchymal transition, tumor cell survival, FOS, transcriptional coactivator, acquired drug resistance, colon cancer, lung cancer, cell transformation, transcriptional regulation
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Colonic Neoplasms, Humans, Lung Neoplasms, Phosphoproteins, Proto-Oncogene Proteins, Transcription Factors, Signal Transduction, Transcriptional Activation, Proto-Oncogene Proteins p21(ras), Drug Delivery Systems, ras Proteins, Cell Cycle Proteins, Drug Resistance, Neoplasm, HCT116 Cells, Adaptor Proteins, Signal Transducing, Mice, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
